| 06/15/2026 3:03 PM | Jasper Therapeutics (1788028) Filer | Form DEF 14A | |
| 06/15/2026 3:03 PM | Jasper Therapeutics (1788028) Filer | Form DEFA14A | |
| 06/15/2026 3:05 PM | Jasper Therapeutics (1788028) Filer | Form ARS | |
| 06/09/2026 3:05 PM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/01/2026 7:01 AM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/14/2026 3:05 PM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/14/2026 3:05 PM | Jasper Therapeutics (1788028) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/12/2026 11:44 AM | Jasper Therapeutics (1788028) Subject MORGAN STANLEY (895421) Filed by | Form SCHEDULE 13G/A | |
| 05/08/2026 4:01 PM | Jasper Therapeutics (1788028) Subject Soleus Capital Master Fund, L.P. (1812275) Filed by | Form SCHEDULE 13G/A | |
| 05/08/2026 12:53 PM | GOLDMAN SACHS GROUP INC (886982) Filed by Jasper Therapeutics (1788028) Subject | Form SCHEDULE 13G/A | |
| 03/30/2026 4:33 PM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for JSPRW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 02/25/2026 3:47 PM | INTEGRATED CORE STRATEGIES (0) US Jasper Therapeutics (1788028) Subject | Form SCHEDULE 13G | |
| 02/12/2026 9:33 AM | GOLDMAN SACHS GROUP INC (886982) Filed by Jasper Therapeutics (1788028) Subject | Form SCHEDULE 13G | |
| 02/11/2026 12:38 PM | Jasper Therapeutics (1788028) Subject MORGAN STANLEY (895421) Filed by | Form SCHEDULE 13G | |
| 01/26/2026 2:29 PM | ACORN BIOVENTURES, L.P. (1766853) Filed by Jasper Therapeutics (1788028) Subject | Form SCHEDULE 13G/A | |
| 01/08/2026 6:06 AM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/07/2026 3:35 PM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/05/2026 6:30 PM | CROSS HERB (1230721) Reporting Jasper Therapeutics (1788028) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 6:30 PM | Jasper Therapeutics (1788028) Issuer Mahal Jeetinder Singh (1882877) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 6:30 PM | Jasper Therapeutics (1788028) Issuer MARTELL RON (1177079) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/02/2025 9:23 AM | ACORN BIOVENTURES, L.P. (1766853) Filed by Jasper Therapeutics (1788028) Subject | Form SCHEDULE 13G | |
| 12/02/2025 6:06 AM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/14/2025 4:22 PM | Jasper Therapeutics (1788028) Subject Qiming U.S. Healthcare Fund II, L.P. (1765710) Filed by | Form SCHEDULE 13G/A | |
| 11/12/2025 12:04 PM | Jasper Therapeutics (1788028) Subject KINGDON CAPITAL MANAGEMENT, L.L.C. (1000097) Filed by | Form SCHEDULE 13G/A | |
| 11/10/2025 7:05 AM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/10/2025 7:17 AM | Jasper Therapeutics (1788028) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/07/2025 11:45 AM | Jasper Therapeutics (1788028) Subject MORGAN STANLEY (895421) Filed by | Form SCHEDULE 13G/A | |
| 09/24/2025 3:01 PM | Jasper Therapeutics (1788028) Issuer Shizuru Judith Anne (1883000) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/24/2025 3:01 PM | Jasper Therapeutics (1788028) Issuer MARTELL RON (1177079) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/24/2025 3:01 PM | Jasper Therapeutics (1788028) Issuer Lucas Svetlana (1781292) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/24/2025 3:01 PM | Jasper Therapeutics (1788028) Issuer WIGGANS THOMAS G (1208907) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/23/2025 4:07 PM | Jasper Therapeutics (1788028) Subject Velan Capital Investment Management LP (1848809) Filed by | Form SCHEDULE 13D/A | |
| 09/19/2025 3:35 PM | Jasper Therapeutics (1788028) Filer | Form 424B5 | |
| 09/19/2025 3:38 PM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/18/2025 3:45 PM | Jasper Therapeutics (1788028) Filer | Form 424B5 | |
| 07/17/2025 7:12 PM | BlackRock, Inc. (2012383) Filed by Jasper Therapeutics (1788028) Subject | Form SCHEDULE 13G/A | |
| 07/11/2025 11:30 AM | Jasper Therapeutics (1788028) Subject KINGDON CAPITAL MANAGEMENT, L.L.C. (1000097) Filed by | Form SCHEDULE 13G | |
| 07/09/2025 7:05 AM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/07/2025 6:35 AM | Jasper Therapeutics (1788028) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/03/2025 3:24 PM | EMSTER KURT VON (1252524) Reporting Jasper Therapeutics (1788028) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/03/2025 3:25 PM | Brun Scott C. (1863614) Reporting Jasper Therapeutics (1788028) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
The energy story near the Grand Canyon (Ad) A drilling crew near the Grand Canyon confirmed what the IEA calls one of the largest energy resources ever measured - enough to meet global electricity demand 140 times over.
They drilled nearly three miles down in just 16 days, a job the Department of Energy projected would take 64. Google signed a 15-year deal. Bill Gates wrote a $100 million check. On July 4th, Washington hands this resource a regulatory edge no other energy source has. See the one company sitting at the center of this discovery |